Moderna Inc

NASDAQ:MRNA   3:59:59 PM EDT
152.51
-4.75 (-3.02%)
5:28:47 PM EDT: $153.19 +0.68 (+0.45%)
Regulatory, Other Pre-Announcement

Moderna’S Covid-19 Vaccine Candidate Meets Its Primary Efficacy Endpoint In The First Interim Analysis Of The Phase 3 Cove Study

Published: 11/16/2020 13:49 GMT
Moderna Inc (MRNA) - Moderna’s Covid-19 Vaccine Candidate Meets Its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 Cove Study.
Moderna Inc - Phase 3 Study Met Statistical Criteria With a Vaccine Efficacy of 94.5% (p